|
T6053 |
Turofexorate Isopropyl
|
XL335,FXR-450,WAY-362450 |
FXR
,
Autophagy
|
|
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM |
|
T40302 |
FXR/TGR5 agonist 1
|
|
|
|
FXR/TGR5 agonist 1 acts as an agonist on both FXR and TGR5 receptors and is utilized for treating fatty liver disease. |
|
T64144 |
FXR antagonist 1
|
|
|
|
FXR antagonist 1 is a selective, orally active intestinal FXR antagonist with an IC50 value of 2.1 μM. FXR antagonist 1 antagonises intestinal FXR and selectively inhibits intestinal FXR signalling by feedback activation... |
|
T74996 |
FXR agonist 3
|
|
|
|
FXR agonist 3, an anti-NASH (Non-Alcoholic Steatohepatitis) agent, functions by activating FXR. It demonstrates anti-fibrogenic activity by inhibiting the expression of COL1A1, TGF-β1, α-SMA, and TIMP1. Additionally, it ... |
|
T72889 |
FXR agonist 4
|
|
|
|
FXR agonist 4 with an EC 50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of ... |
|
T75160 |
FXR agonist 5
|
|
|
|
FXR agonist 5 (compound 1), an FXR agonist, is utilized in research targeting diseases or disorders associated with metabolic inflammation [1]. |
|
T74754 |
FXR antagonist 2
|
|
|
|
Compound A-26, also known as FXR antagonist 2, is a diarylamide derivative that functions as a moderate FXR antagonist. It is utilized in researching hyperlipidemia and type 2 diabetes [1]. |
|
T2015 |
Fexaramine
|
|
FXR
,
Autophagy
|
|
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity compared to natural compounds. |
|
T2233 |
GW 4064
|
|
FXR
,
Autophagy
|
|
GW 4064 is an effective farnesoid X receptor (FXR) agonist (EC50 =65 nM). |
|
T7886 |
Nidufexor
|
|
FXR
,
Autophagy
|
|
Nidufexor is an agonist for the farnesoid X receptor (FXR). |
|
T15806 |
LY2562175
|
|
FXR
,
Autophagy
|
|
LY2562175 is an effective and selective FXR agonist (EC50: 193 nM). |
|
T6344 |
Sevelamer hydrochloride
|
Sevelamer HCl |
FXR
,
Autophagy
|
|
Sevelamer hydrochloride (Sevelamer HCl) is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption. |
|
T7436 |
Cilofexor
|
|
FXR
,
Autophagy
|
|
Cilofexor inhibits binding of a synthetic peptide, Cilofexor is a farnesoid X receptor (FXR) agonist. |
|
T31587 |
DY268
|
DY 268,DY-268 |
FXR
|
|
DY268 is a compound based on trisubstituted pyrazolamide without any FXR agonist activity and cytotoxicity and can be used as an effective FXR antagonist (IC50 = 7.5 nM). |
|
T4379 |
Tropifexor
|
LJN452 |
FXR
,
Autophagy
|
|
Tropifexor (LJN452) is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM. |
|
T11428 |
Glyco-Obeticholic acid
|
|
FXR
|
|
Glyco-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an agonist of the farnesoid X receptor (FXR). |
|
T2601 |
Vidofludimus
|
SC12267,4sc-101 |
Dehydrogenase
,
DNA/RNA Synthesis
,
Interleukin
|
|
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). |
|
T8471 |
Vonafexor
|
EYP001,PLX007,pxl007 |
FXR
,
HBV
|
|
Vonafexor (EYP001) is a farnesoid X receptor (FXR, NR1H4) agonist, with anti-HBV effects |
|
TQ0252 |
BAR502
|
|
FXR
,
GPCR19
,
Autophagy
|
|
BAR502 is a dual GPBAR1 and FXR agonist (IC50s: 0.4 μM and 2 μM). |
|
T1789 |
Obeticholic Acid
|
INT-747,6-Ethylchenodeoxycholic acid,6-ECDCA |
FXR
,
Autophagy
|
|
Obeticholic Acid (6-ECDCA) is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist. |
|
T6690 |
T0901317
|
|
Apoptosis
,
FXR
,
Liver X Receptor
,
ROR
|
|
T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB). |
|
T27460 |
GSK2324
|
GSK-2324,GSK 2324 |
FXR
|
|
GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis. |
|
T11426 |
Gly-β-MCA
|
|
FXR
|
|
|
|
T63042 |
NDB
|
|
FXR
|
|
NDB is a selective and potent hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions and FXRα target gene expression in primary mouse hepatocytes.NDB is used in the study of diabetes. |
|
T8818 |
TC-G 1005
|
|
GPCR19
|
|
TC-G 1005 is a potent and selective GPBA agonist (EC50 :0.72 nM; hTGR5). Selective for TGR5 over FXR (farnesoid X receptor). Increases plasma GLP-1 levels and reduces blood glucose in mice. Orally available. |
|
T12583 |
PX20606 trans racemate
|
PX-102 trans racemate |
Others
|
|
PX20606 trans racemate is an agonist of FXR (EC50s of 32 and 34 nM for FXR in FRET and M1H assay, respectively). |
|
T13093 |
Tauro-β-muricholic acid sodium
|
T-βMCA sodium |
FXR
|
|
Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM). |
|
T68612 |
DM175
|
|
|
|
DM175 is a novel partial FXR agonist, causing specific modulatory effects on FXR activity that clearly differ from classical FXR agonists. |
|
T25417 |
Fexarene
|
|
|
|
Fexarene is a non-steroidal FXR agonist. |
|
T24837 |
ST-1892
|
|
|
|
ST-1892 is a soluble partial FXR agonist. |
|
T27492 |
GSK-8062
|
GSK 8062 |
|
|
GSK-8062 is an agonist of farnesoid X receptor (FXR). |
|
T73414 |
EDP-305
|
|
|
|
EDP-305, an orally active, potent, and selective agonist of the farnesoid X receptor (FXR), exhibits EC50 values of 34 nM in chimeric FXR within CHO cells and 8 nM in full-length FXR in HEK cells. Demonstrating a potent ... |
|
T12251 |
NR1H4 activator 1
|
|
Others
|
|
NR1H4 activator 1 is a potent and selective agonist of Famesoid X Receptor (FXR). |
|
T63818 |
Omesdafexor
|
|
|
|
Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation. |
|
T69724 |
Cilofexor tromethamine
|
|
|
|
Cilofexor, also known as GS-9674, is a farnesoid X receptor (FXR) agonist. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. In clinical study, cilof... |
|
T37414 |
CAY10771
|
|
|
|
CAY10771 is a dual agonist of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor δ (PPARδ).1It activates FXR and PPARδ in reporter assays using HEK293T cells (EC50s = 0.94 and 1.5 μM, respectively)... |
|
T70899 |
Vidofludimus hemicalcium
|
4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium |
|
|
Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulat... |
|
T11661 |
INT-767
|
|
FXR
,
GPCR19
|
|
INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis. |
|
T69686 |
BMS-986318
|
|
|
|
BMS-986318 is a potent nonbile acid FXR agonist, displaying EC50 values of 53 nM and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. It exhibits a favorable ADME profile and shows effectiveness in mouse mo... |
|
T78910 |
ZLY28
|
|
FXR
|
|
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of n... |
|
T37416 |
Tauro-α-muricholic Acid (sodium salt)
|
|
|
|
Tauro-α-muricholic acid (TαMCA) is an antagonist of the farnesoid X receptor (FXR; IC50 = 28 μM) and a taurine-conjugated form of the murine-specific primary bile acid α-muricholic acid . TαMCA is common in rodents but h... |
|
T73155 |
BMS-986339
|
|
|
|
BMS-986339 is an orally active, potent FXR agonist that interacts via H-bond formation with the His298 and ASN287 residues. It is utilized in research focused on primary biliary cirrhosis (PBC), primary sclerosing cholan... |
|
T83858 |
Tauro-Obeticholic Acid sodium
|
Tauro-6-Ethylchenodeoxycholic Acid,Tauro-6-Ethyl-CDCA,Obeticholic Acid Taurine Conjugate,Tauro-OCA,T-ECDCA |
|
|
Tauro-obeticholic acid, a farnesoid X receptor (FXR) agonist and semisynthetic derivative of chenodeoxycholic acid, is an active metabolite of obeticholic acid. This compound undergoes taurine conjugation in the liver to... |
